Royal London Asset Management Ltd. Sells 4,597 Shares of STERIS plc $STE

Royal London Asset Management Ltd. lowered its position in STERIS plc (NYSE:STE) by 0.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 502,704 shares of the medical equipment provider’s stock after selling 4,597 shares during the period. Royal London Asset Management Ltd. owned about 0.51% of STERIS worth $127,446,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of STE. Board of the Pension Protection Fund bought a new position in STERIS in the 4th quarter worth $25,000. Harbor Investment Advisory LLC boosted its holdings in STERIS by 115.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 60 shares during the period. Activest Wealth Management boosted its holdings in STERIS by 423.8% in the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 89 shares during the period. Measured Wealth Private Client Group LLC bought a new position in STERIS in the 4th quarter worth $28,000. Finally, Geneos Wealth Management Inc. boosted its holdings in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the period. Institutional investors own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on STE. KeyCorp dropped their target price on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Piper Sandler reissued an “overweight” rating and set a $270.00 price objective on shares of STERIS in a report on Thursday, May 21st. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, STERIS has an average rating of “Moderate Buy” and an average price target of $278.00.

Insider Buying and Selling at STERIS

In other news, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction on Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the completion of the sale, the chief executive officer directly owned 63,647 shares in the company, valued at approximately $13,493,164. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of STERIS stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total transaction of $310,284.31. Following the sale, the director owned 38,964 shares of the company’s stock, valued at $8,163,347.64. The trade was a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,909 shares of company stock valued at $1,257,083 over the last quarter. Insiders own 1.07% of the company’s stock.

STERIS Stock Performance

Shares of STE stock opened at $207.50 on Friday. The company’s 50 day moving average is $216.08 and its 200 day moving average is $237.38. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44. The firm has a market cap of $20.25 billion, a price-to-earnings ratio of 26.17 and a beta of 0.93.

STERIS (NYSE:STE) last released its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same period in the prior year, the firm posted $2.74 earnings per share. STERIS’s revenue for the quarter was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, sell-side analysts anticipate that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s payout ratio is presently 31.78%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.